MarketResearchReport2021

Myasthenia Gravis Disease Market The surging cases of neuromuscular disorders are estimated to favor the market growth globally. Myasthenia gravis is referred to as a neuromuscular disorder which results in the skeletal muscles to weaken. The Myasthenia Gravis Disease Market is projected to reach USD 1.9 Billion by 2030 at 7.70% CAGR during the forecast period 2022-2030. The disease generally occurs due to the impairment of communication between the nerve cells and the muscles and causes difficulty in the relaxation and contraction of muscles. The antibodies present in the body destroy the receptor for acetylcholine at the neuromuscular joint which prevents the muscles from contracting and performing its normal function. Major Key Players: Leading Myasthenia Gravis Disease Market Players are Fresenius Kabi, GSK plc, AbbVie Inc., Biogen Inc., Bristol-Myers Squibb Co., F. Hoffman-La Roche Ltd., Cipla, RPG Life Sciences, Teva Pharmaceutical Industries Ltd., Apotex Corporation,

  Myasthenia Gravis Disease Market The surging cases of neuromuscular disorders are estimated to favor the market growth globally. Myasthenia gravis is referred to as a neuromuscular disorder which results in the skeletal muscles to weaken. The  Myasthenia Gravis Disease Market  is projected to reach USD 1.9 Billion by 2030 at 7.70% CAGR during the forecast period 2022-2030. The disease generally occurs due to the impairment of communication between the nerve cells and the muscles and causes difficulty in the relaxation and contraction of muscles. The antibodies present in the body destroy the receptor for acetylcholine at the neuromuscular joint which prevents the muscles from contracting and performing its normal function. Major Key Players: Leading players in the global myasthenia gravis disease market include Fresenius Kabi, GSK plc, AbbVie Inc., Biogen Inc., Bristol-Myers Squibb Co., F. Hoffman-La Roche Ltd., Cipla, RPG Life Sciences, Teva Pharmaceutical Industries Ltd., Apotex Co